Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by PinnacleXon Jan 04, 2022 5:04pm
186 Views
Post# 34283224

RE:RE:RE:My opinion

RE:RE:RE:My opinion
jeffm34 wrote:

Realitycheck4u, since you've been here for a long while how many times have you thought "just another few months" ?  Through the false sales estimates, the new sales team, European approval, F8, IV push, NASH trial starting, NASH partnership coming, Oncology results in 2021, oncology results in early 2022 now, if there is no efficacy to report in part 1 then we wait another 6 months. The only thing this company has been consistently good at is moving on from one failure by creating hope in the next inevitable failure 

 

realitycheck4u wrote:

 

I understand the frustration. I've been in this too for a long while. However, this does seem different on a substantial level. Paul has said his piece and he said 1st qtr 2022. He has also brought solid plans and is building a team.  This could be different. We will see end of March. Patience is still needed here. Not much longer. 


 

Momo25 wrote: I am not a scientist and I don't care about the science per say. I care about the money I have invested in this company when the share was at  $15. I am still above 6$ a share in average . TH executives have no clue about the shareholders Return Of Investment. I see some of you trying to justify Paul's and the board attitudes. Those are  a gang of losers not business men.

 

 




Finally, a guy with common sense.  The rest of the fanboys will defend this when its at 10 cents, the same way they are now. 
<< Previous
Bullboard Posts
Next >>